Press Release
NonageN THERAPEUTICS’ ISSUED a 2nd PATENT ON TARGETING HUMAN CHEMOKINE LIGAND 1 (CXCL1)
Los Angeles, CA, April 12, 2022 – USPTO officially issued Nonagen Therapeutics’ patent (US 11,292,832), which further reports methods on modulating the activity of human Chemokine Ligand 1 (CXCL-1) protein with a humanized monoclonal antibody. This further bolster Nonagen’s stance in targeting CXCL1, a key molecule involved in angiogenesis and modulating the local immune landscape. By neutralizing CXCL1 with its antibodies, Nonagen Therapeutics is one step closer to applying its technology for the treatment of diseases involving CXCL1 function, for example, pathological angiogenesis, inflammatory diseases and cancers.
‘Our patents on targeting CXCL1 are the premise behind Nonagen Therapeutic’s strategy to target the microenvironment of pathological conditions as an effective treatment option.’ stated Charles Rosser, CEO/CMO Nonagen Therapeutics.
NonageN THERAPEUTICS’ PATENT ON TARGETING HUMAN CHEMOKINE LIGAND 1 (CXCL1) ISSUED
Los Angeles, CA, March 18, 2022 – USPTO officially issued Nonagen Therapeutics’ patent (US 11,267,881), which reports methods on modulating the activity of human Chemokine Ligand 1 (CXCL-1) protein. CXCL1 is involved in cell survival, angiogenesis, local immune suppression as well as growth of fibroblasts. In particular, Nonagen Therapeutics has identified and developed monoclonal antibodies capable of being used as a medicament for the prevention and/or treatment of diseases involving CXCL1 function, for example, pathological angiogenesis, inflammatory diseases and cancers. ‘This patent begins to lay the foundation for Nonagen Therapeutic’s premise that targeting the microenvironment of pathological conditions can be a safe and effective way in treating a variety of ailments.’ stated Charles Rosser, CEO/CMO Nonagen Therapeutics.
Nonagen’s Scientist receives NIH/NCI grant to study the biology behind targeting CXCL1
Los Angeles, CA, August 1, 2021 – NIH/NCI awarded Nonagen Therapeutics’ senior scientist a grant entitled ‘Humanized anti-CXCL1 antibody for bladder cancer therapeutics’, which hypothesizes neutralization of CXCL1 by humanized monoclonal antibody can be a potent strategy for bladder cancer therapy. Specifically, the researcher will study whether NTC-001 exhibits any inhibitory effects on angiogenesis and tumor growth in vivo and any inhibitory effects in a novel humanized mouse model. The significance of this work rests on laying the foundation to moving this therapeutic towards the clinic where it could possess a huge impact in the care of cancer patients.
Nonagen Therapeutics Corporation EstablisheS SCIENTIFIC ADVISORY BOARD
Los Angeles, CA, May 12, 2021 – Nonagen Therapeutics is pleased to welcome Drs. Omid Hamid and Brian Issell to our Scientific Advisory Board. Dr. Hamid is the Director of the Melanoma Center and Chief of Translational Research & Immuno-Oncology at The Angeles Clinic and Research Institute (TACRI) and is world renowned for his work on innovative phase 1 clinical trials. Dr. Issell, emeritus Professor at the University of Hawaii’s NCI designated cancer center, is an academic and industry veteran, who pioneered the use of IL-2 and cisplatin in oncology, transforming modern day oncology. Their expertise and knowledge will be invaluable as we tackle difficult, yet important opportunities in cancer.
Nonagen Therapeutics Corporation Established
Los Angeles, CA, Oct 13, 2020 – Nonagen Therapeutics Corporation today announced its incorporation as a C-Corp in the State of Delaware with a primary business address of 3680 Wilshire Blvd Los Angeles, CA 90010. Nonagen Therapeutics, a spin off of Nonagen Bioscience Corporation, a molecular diagnostic company, is geared to bring first in human novel therapeutics to the clinic to alleviate human diseases.
Nonagen Therapeutics’ leadership team includes; Dr. Jeffrey Huang, Senior Regulatory Associate; Dave Mori, Chief Development Officer; Dr. Steve Goodison, Chief Scientific Officer and Dr. Charles J. Rosser, CEO.